HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $135M
Founded date: 2021
Investors 6
| Date | Name | Website |
| - | Spur Capit... | spurcapita... |
| 17.09.2021 | Lightspeed... | lsvp.com |
| 08.09.2021 | RA Capital... | racap.com |
| 15.09.2021 | Abingworth... | abingworth... |
| - | Sahsen Ven... | sahsen.com |
| 02.12.2021 | Catalys Pa... | catalyspac... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.09.2021 | - | $135M | - |
Mentions in press and media 7
| Date | Title | Description |
| 08.09.2021 | HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate | HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, today announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and join... |
| 08.09.2021 | Takeda's norovirus vaccine spinout, HilleVax, secures $135M crossover How to Optimize In Vitro and In Vivo Data Analysis and Data Management in Drug Research | HilleVax has garnered a whopping $135 million in investor interest two months after spinning out of Takeda to take on norovirus. RELATED: Takeda allies with Frazier to spin out late-phase norovirus vaccine HilleVax wants to make the first a... |
| 08.09.2021 | HilleVax Closes $135M Crossover Financing | BOSTON, MA, HilleVax, a biopharmaceutical company, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners. >> Click here for more funding data on HilleVax >> To export HilleVax funding d... |
| 08.09.2021 | HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate | Boston, Mass., September 8, 2021 – HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, today announced the close of a $135 million crossover financing led by F... |
| 08.09.2021 | Takeda's norovirus vaccine spinout, HilleVax, secures $135M crossover | HilleVax has garnered a whopping $135 million in investor interest two months after spinning out of Takeda to take on norovirus. In late July, Takeda offloaded its phase 2b norovirus asset to form HilleVax with investor Frazier Healthcare P... |
| 30.07.2021 | Takeda and Frazier Healthcare Partners announce collaboration to launch HilleVax, Inc. to develop clinical stage Norovirus Vaccine Candidate | India: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE: TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commerciali... |
| 29.07.2021 | Takeda Pharmaceutical : and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. | Cambridge, Mass. and Menlo Park, Calif., July 29, 2021 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a bio... |